Cardiff Oncology Inc CRDF

$0.73 0.00 (-0.21%)

Valuation

Market cap
56,604,000
Revenue TTM
$590,000
Net income TTM
$-45,850,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-7,771.19%
Debt to equity
0.00

Trading

Volume
205,100
Avg volume
577,296
Day's range
$0.71 – $0.74
Shares out
77,795,000
Stochastic %K
8%
Beta
1.57
Analysts
Moderate Buy
Price target
$6.28

Price

Company profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreati...

Show more

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 952 7570
Website
https://www.cardiffoncology.com
Address
11055 Flintkote Avenue, San Diego, United States

Latest news

Stocktwits

lonedaddy Nov 14, 1:15 AM
$CRDF lets hope Mani‘s flight goes
1 replies
McGinvests Nov 13, 9:22 PM
$CRDF All the new hire tells us is that there is no deal.
0 replies
rag2riches Nov 13, 9:15 PM
$CRDF told yall mani was cooking something special for UBS in bringing a business development advisor to this.
3 replies
JN75 Nov 13, 8:51 PM
$CRDF a little info on Zai Lab
0 replies
Teskonik Nov 13, 8:49 PM
$CRDF in no mans land.
0 replies
JN75 Nov 13, 8:48 PM
$CRDF a little info on new hire
1 replies
DD_investments Nov 13, 8:26 PM
$CRDF honestly things are pointing towards someone else taking over or at least a partnership. New hire is a business development role, they’ve seemingly wound down clinical roles, new interim CMO is on a contract until April (happens to be right after their estimated ph2 completion). Let’s see if we get some real juicy mCRC updates on Monday or if they reference a March data cut again lol
1 replies
Core366 Nov 13, 8:25 PM
$CRDF November tuesday 24th will be the 30th consecutive day under a dollar...retail should be able to push it over a dollar by then, but lets see...
0 replies